Posts in Category: Cancer

Mikhail Blagosklonny Leading the Fight against Cancer

Mikhail Blagosklonny is currently a professor of Oncology at Rosewell Park Cancer Institute located in Buffalo, New York and Chief Editor of Oncortarget. Blagosklonny has been for many years now at the forefront in researching cancer; its therapies and aging. He is famously known for spearheading the use of Rapamycin a cancer drug that helps increase the lifespan of human beings. Rapamycin is a drug that is commonly used for the prevention of organ transplant rejection. The drug which is also known as Sirolimus is used in the coating of coronary stents and the treatment of a rare lung disease. Rapamycin is also a popular cancer drug. The drug was previously used as an anti-fungal agent, but because of its immunosuppressive and antiproliferative properties, doctors stop using it as an anti-fungal agent.Rapamycin immunosuppressant properties play a very critical role when it comes to organ transplant. During organ transplant the body naturally tends to reject foreign organs. For an organ transplant to be successful doctors, recommend the use of anti-rejection drugs or immunosuppressive drugs. However, most of these drugs have adverse effects on the kidneys, and that’s where Rapamycin scores highly as compared to the other immunosuppressive drugs as it has very minimal toxicity level towards the kidney.

Rapamycin is also best for treating hemolytic-uremic syndrome a condition which results from a combination of anemia, kidney failure, and low platelet count. As a result, a patient suffering from the disease is required to have a kidney transplant where one has to use the immunosuppressive drugs to prevent organ rejection. The drugs due to its toxicity nature to the kidney may affect the new kidney thus the use of Rapamycin is recommended to lower the toxicity level. Another use of Rapamycin is in the treatment of Lymphangioleiomyomatosis (LAM) which is a rare lung disease that affects mature women. Also, the drug is used for coronary Stent coating where it prevents the occurrence of re-stenosis in the arteries after a balloon angioplasty procedure. The antiproliferative properties of Rapamycin are used in the treatment of cancer. The drug helps boost the body immune system towards tumors and promotes tumor regression thereby limiting cancer in patients with an organ transplant. Other uses of Rapamycin include the treatment of Tuberous Sclerosis Complex (TSC), Facial Angiofibromas, Muscular Dystrophy, Alzheimer, Systemic Lupus Erythematosus and increase in person’s longevity among others.

One particular area of interest for Mikhail Blagosklonny is the area of cancer as well as aging. Mikhail is interested in specifically knowing what the relationship between the two is as cancer mostly attacks individuals at old age. Mikhail continues to research the field of oncology with the aim of not only finding a way of treating cancer but also to find a method of treatment that will be affordable to many. In addition, Blagosklonny wants to figure out a way in which cancerous cells can be destroyed without affecting the normal cells that are crucial to recovery.Mikhail has made much progress in the field of medicine and cancer treatment and hopes that his findings will inspire others even to do more in the industry. Mikhail endeavors to see that the treatment of cancer is not a preserve of the wealthy in the society who can comfortably afford the treatment but instead it should be an easy and cost-effective type of treatment that is accessible to all regardless of an individual’s financial status.

Eric Lefkofsky and his Accelerated Disruption Initiative

Disruptive businesses come up every day. A person hatches an idea that is convenient in terms of price, functionality, or service. This person is on the verge of reinventing an entire industry. However, due to miscalculation and a lack of vision, this same person fails to factor the ever changing technology trends. In a short time, the forces of technology cause this person to face challenges from startups or large competitors and they are eventually overtaken. This is the idea behind Accelerated Disruption and more information click here.

What Exactly is Accelerated Disruption?

Accelerated Disruption refers to a business development that moves at the same pace as new technological trends. Businesses that have an understanding of technology and can control its forces have a bright future in contract to those that do not and learn more about Eric.

Accelerated Disruption is involved with the following startup concepts:

  • Choosing the appropriate industries to innovate
  • Converting a business’s client base into a sophisticated team
  • Understanding pain and turning it to a business’s advantage
  • Using conventional wisdom to study disruptive ideas and test them under the radar
  • Perfecting the skill of quick-release product alterations
  • Using smart automation to get the best from people
  • Promoting an idea when faced with investor and industry resistance
  • Coming up with a capital strategy that will support a business during the important phases of development

Eric Lefkofsky’s Philanthropic Activities

Lefkofsky partnered with his wife to establish a trust in 2006. The trust was named “Lefkofsky Family Foundation“. The mission of the foundation is to support charitable, educational, and scientific causes and organizations worldwide. The purpose of this foundation is to promote high-impact programs, research, and initiatives that affect humanity’s quality of life. The foundation evaluates its grant making on a quarterly basis, and chooses grants that are focused on a few key areas, including human rights, education, arts and culture, and medical research. A huge portion of the funds are invested in Chicago, Lefkofsky’s hometown and Eric’s lacrosse camp.

More Visit:

“Eric Lefkofsky’s Commitment to Transforming Patient Outcomes through Genomic Clinical Data”

“The Greater Effort toward Tomorrow’s Medical Horizon”

In addressing the National Medical Association, William J. Mayo spoke concerning the ideals and aims of the American Medical Association. Emphasizing the practice of medicine is patient’s benefit, he said, “The glory of medicine is that it is constantly moving forward, that there is always more to learn. The ills of today do not cloud the horizon of tomorrow, but act as a spur to greater effort.”

Creating partnerships with medical healthcare industries worldwide, a prosperous entrepreneur, Eric Lefkofsky pursues life-changing work of transforming cancer patient outcomes with innovative treatment decisions by delivering clinically serviceable diagnostics. His mission utilizes genomics, a division of biotechnology through the application of genetics and molecular biology to the mapping of genetics and DNA sequencing of gene sets. As a generous philanthropist, he has established charitable trust called the Lefkofsky Foundation, promoting the support of scientific, charitable, and educational organizations and causes around the globe.

“Redefining Genomic Clinical Data- Personalizing the Approach”

Eric Lefkofsky co-founded Tempus, a technology platform connecting molecular and anatomic data with clinical data from worldwide medical institutions, which personalizes the approach in battling cancer. As the CEO, Eric Lefkofsky has the objective of improving patient outcomes, providing physicians with implements that acquire learning techniques through data technology application for clinical care, delivering on the genomics promise. The aim is for every patient to benefit from other previous patient treatments.

“Challenging the Status Quo through Unwavering Commitment”

Eric Lefkofsky trusts that Tempus can become the Therapeutic Holy Grail, perceiving that, “The aim of medicine is to prevent disease and prolong life, the ideal of medicine is to eliminate the need of a physician.” Through his avid philanthropy and brilliant education, Eric Lefkofsky possesses a motivated commitment toward conveying applicable technology toward cancer, with the ultimate goal of applying this knowledge to treatment in attacking the most challenging medical problem known to man on our planet today.

About Eric Lefkofsky: